Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MNKD
MANNKIND CORPORATION
NASDAQ
$3.95
▼ DOWN 2.71% (-0.11)

KEY STATISTICS

Market Cap$1.26 B
52w High$6.51
52w Low$2.23
Dividend Yield—
Frequency—
P/E-30.38
Volume1.98M
Shares Out.319.39M

COMPANY

LEADERSHIP

Michael E. Castagna
CHIEF EXECUTIVE
Michael E. Castagna

COMPENSATION 2026

Salary$789,436
Stock Awards$7,689,480
Incentive Plan Pay$675,757
All Other Comp.$145,812
Total$9,300,485

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 28, 2004
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
592

PRICE TARGET

Target High$13.00
Target Low$6.00
Target Median$8.50
Target Consensus$9.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$110.25M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2017-03-03Reverse1:5

PRICE

$3.95 ▼ DOWN 2.71% (−$0.11)
OVERLAYS
$3.96$4.00$4.049:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.95

About MannKind Corporation

https://www.mannkindcorp.com ↗

MannKind Corporation develops inhaled therapies like Afrezza for diabetes and collaborates on treatments for lung and endocrine diseases, headquartered in Westlake Village, California.

INDUSTRY

Biotechnology

A PRODUCT MANNKIND CORPORATION IS KNOWN FOR

Afrezza (insulin human) Inhalation Powder
Afrezza (insulin human) Inhalation Powder

Afrezza is the only approved rapid-acting inhaled insulin for adults with type 1 and 2 diabetes, delivering quick blood sugar control via a portable inhaler.

COMPETITORS

COMPETITOR
AZN COMPARE
LLY COMPARE
MRK COMPARE
NVO COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product Revenue$48.27M $123.57M ▲$55.92M ▼$71.58M ▲
Royalty$33.32M $33.56M ▲$32.75M ▼$32.37M ▼
Service$537K $3.17M ▲$1.5M ▼$5.42M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
126
LISTED HERE
24
RANKED BY POSITION SIZE
VTS.AX
0.00% · 9.3M
XBI
0.31% · 9.1M
XSU.TO
0.04% · 7.9M
JSMD
0.64% · 1.7M
SCHA
0.03% · 1.5M
FYC
0.37% · 1.3M
SFLO
0.36% · 703.3K
SBIO
0.62% · 381.1K
LABU
0.21% · 330.2K
XRS2.DE
0.04% · 281.7K
RSSL
0.04% · 147.0K
FHLC
0.02% · 140.7K
GSSC
0.02% · 65.0K
DFAC
0.00% · 58.4K
EES
0.03% · 55.9K
QQQS
0.52% · 29.7K
TILT
0.00% · 23.7K
URTY
0.02% · 12.5K
LITL
0.66% · 11.5K
VETS
0.08% · 8.9K
KBFR
0.06% · 1.5K
USFMDN.MX
0.00% · 1.4K
AVUQ
0.00% · 1.3K
RESM
0.04% · 576

INSTITUTIONAL OWNERSHIP

SHARES OWNED
49.74%
HOLDERS
380
TOP 12 OF 380 · RANKED BY POSITION SIZE
Blackrock, Inc.
32.1M sh · $136.89M
Blackrock Inc.
22.6M sh · $117.75M
State Street Corp
18.7M sh · $45.77M
Rubric Capital Management LP
18.0M sh · $76.68M
Vanguard Group Inc
17.9M sh · $101.38M
Ubs Group AG
8.3M sh · $20.23M
Geode Capital Management, LLC
7.9M sh · $33.86M
Wellington Management Group Llp
7.8M sh · $33.42M
Frazier Life Sciences Management, L.P.
6.6M sh · $28.12M
Nitorum Capital, L.P.
6.6M sh · $35.24M
Millennium Management LLC
6.4M sh · $15.66M
Deep Track Capital, LP
6.0M sh · $25.56M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Binder Steven B.
Sale · 39.1K shares
2026-08-07
★
OFFICER: EVP GENL COUNSEL & SECRETARY
Thomson David
Sale · 51.6K shares
2026-07-15
★
OFFICER: EVP GENL COUNSEL & SECRETARY
Thomson David
Sale · 17.8K shares
2026-07-15
★
OFFICER: EVP GENL COUNSEL & SECRETARY
Thomson David
Sale · 16.4K shares
2026-07-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 3
OVERWEIGHT 1
BUY 1
SECTOR PERFORM 1
6 GRADES IN THE LAST 12 MONTHS
Wells Fargo OVERWEIGHT HC Wainwright & Co. BUY Mizuho OUTPERFORM RBC Capital SECTOR PERFORM Wedbush OUTPERFORM Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
ABCL$11.35COMPARE
CLDX$39.12COMPARE
VERA$34.19COMPARE
BHVN$15.41COMPARE
NUVB$6.66COMPARE
HRMY$39.21COMPARE
AUPH$16.29COMPARE
IMCR$36.62COMPARE